CoChat

Therapeutic Potential of Iron Chelators in Cancer Therapy

Richardson, Des R. · 2002 · Advances in Experimental Medicine and Biology

The DOI matches its Crossref record; 106 of the 108 references it cites were found in a registry or an index.

Abstract

The success of DFO at markedly inhibiting the growth of aggressive tumors such as neuroblastoma and leukemia justifies interest in the development of chelators as anti-neoplastic agents. This is emphasized by the fact that DFO has suboptimal properties, namely poor membrane permeability and a very short serum half-life. More recently, the thiosemicarbazone chelator, Triapine, has entered a phase I clinical trial again confirming the potential of these compounds. Further studies examining the effects of chelators on neoplastic cells will not only be valuable in terms of identifing novel anti-cancer agents, but will also provide new information on the role of Fe in cell cycle control.

Overview

Integrity signals

Registry

Crossref · 10.1007/978-1-4615-0593-8_12

Cites

106 of 106 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 106 references

Research works printed but not linked: 6

  1. Richardson, D.R., 1997, Iron chelators as effective anti-proliferative agentsCan. J. Physiol. Pharmacol.75:1164. · doi:10.1139/y97-156 · Paper page
  2. Beckloff, G.L., Lerner, H.1., Frost, D., Russo-Alesi, F.M., and Gitomer, S., 1965, Hydroxyurea (NSC-32065) in biological fluids: Dose-concentration relationshipCancer Chemother. Rep.48:57.
  3. Brodie, C., Siriwardana, G., Lucas, J., Schleicher, R., Terada, N., Szepesi, A., Gelfand, E., and Seligman, P., 1993, Neuroblastoma sensitivity to growth inhibition by deferoxamine: Evidence for a block in the GIphase of the cell cycleCancer Res.53: 3968.
  4. Blatt, J., and Stitely, S., 1987, Antineuroblastoma activity of desferrioxamine in human cell linesCancer Res.47:1749.
  5. Hoyes, K.P., Hider, R.C., and Porter, J.B., 1992, Cell cycle synchronization and growth inhibition by 3hydroxypyridin-4-one iron chelators in leukemic cell linesCancer Res.52: 4591.
  6. Bi, S., Hughes, T., Bungey, J., Chase, A., de Fabritiis, P., and Goldman, J.A., 1992, sp53 in chronic myeloid leukemia cell lineLeukemia6: 839

Cited by

See all 41

Metadata

Authors
Richardson, D. R.
Affiliations
The Heart Research Institute (AU)
Corresponding author
Richardson, Des R.
Venue
Advances in Experimental Medicine and Biology
Publisher
Springer US
Published
2002
Volume
509
Pages
231-249
ISSN
0065-2598 (ISSN-L)
OpenAlex
W61704258
Cited by
40
References
108
Citations by year
2022: 1 · 2021: 3 · 2019: 3 · 2018: 1 · 2016: 2 · 2015: 3 · 2013: 2 · 2012: 1
FWCI
8.02
Type
book chapter
Language
en
Open access
closed
Locations
  • Advances in experimental medicine and biology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
  • Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
Keywords
iron chelators, cancer therapy, deferoxamine, oral iron chelators, iron metabolism
MeSH terms
Animals, Antineoplastic Agents, Cell Cycle, Deferoxamine, Humans, Iron, Iron Chelating Agents, Isoniazid, Neoplasms, Pyridoxal, Thiosemicarbazones, Tumor Suppressor Protein p53

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic Potential of Iron Chelators in Cancer Therapy. https://app.cochat.ai/papers/10.1007/978-1-4615-0593-8_12
The paper
Richardson, D. R. (2002). Therapeutic Potential of Iron Chelators in Cancer Therapy. Advances in Experimental Medicine and Biology. https://doi.org/10.1007/978-1-4615-0593-8_12

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.